Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06952634 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
A Phase 1 study of Hepatic Impairment, sponsored by Alumis.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT06952634 is a Phase 1 study of Hepatic Impairment that is actively recruiting participants, run by Alumis. The registered enrollment target is 48 participants, above the 35-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (37% higher). The trial reports 4 study locations across 3 states.
The verdict
NCT06952634, a Phase 1 study of Hepatic Impairment, is actively recruiting participants, sponsored by Alumis.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.
Conditions Studied
Interventions
- DRUG ESK-001
Study Locations (4)
Florida
- Panax Clinical Research - Miami Lakes
- Orlando Clinical Research Center - Orlando
California
- Orange County Research Center - Lake Forest
Tennessee
- Alliance for Multispecialty Research - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-04-29 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06952634
The ClinicalTrials.gov registry entry for NCT06952634 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 35-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (37% higher). The listed sponsor is Alumis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatic Impairment appearing as the primary indexed condition, and to 1 intervention - of which ESK-001 is the first listed.
NCT06952634 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06952634 about?
NCT06952634 is a clinical study titled "An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage". This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.
What is the current status of trial NCT06952634?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-04-29. Estimated completion is 2025-12.
What conditions does trial NCT06952634 study?
This clinical trial studies the following conditions: Hepatic Impairment.
What interventions are being tested in trial NCT06952634?
The interventions under investigation include: ESK-001 (DRUG).
Who is sponsoring clinical trial NCT06952634?
This trial is sponsored by Alumis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06952634 being conducted?
This trial has 4 study locations across California, Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
RECRUITING · Phase 1
-
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
RECRUITING · Phase 1
-
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
RECRUITING · Phase 1
-
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
RECRUITING · Phase 1
-
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.